


# GECONEU NEWS



frontiers | Frontiers in Genetics | Sections | Articles | Research Topics | Editorial Board | About journal | Submit your research | Search | Login

ORIGINAL RESEARCH article  
Front. Genet., 15 December 2023  
Sec. Genetics of Aging  
Volume 14 - 2023 | <https://doi.org/10.3389/fgene.2023.1305107>




This article is part of the Research Topic  
Rising Stars in Genetics of Aging: 2023  
[View all Articles >](#)


**Download Article** ▾


**1,655** Total views  
**50** Downloads

[View article impact >](#)

[View altmetric score >](#)

SHARE ON   

Edited by  
 **Paolina Crocco**  
University of Calabria, Italy

Reviewed by  
 **Francesco Bruno**

<sup>1</sup> Network Aging Research (NAR), Heidelberg University, Heidelberg, Germany  
<sup>2</sup> 1st Department of Neurology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki.

## Feature Article: Exploring Attitudes toward Pre-symptomatic Screening for Alzheimer & Dementia in Five European Countries

In the latest edition of Frontiers in Genetics, the GECONEU project (Genetic counseling in European universities: The case of neurodegenerative diseases) sheds light on attitudes toward pre-symptomatic screening for Alzheimer's Dementia (AD) across five European countries. The study, titled "Attitudes toward pre-symptomatic screening for Alzheimer's Dementia in five European countries: a comparison of family members of people with Alzheimer's Dementia versus non-family members", investigates the acceptance of screening among family and non-family members in Belgium, Germany, Greece, Spain, and Turkey. The research, using the Perceptions regarding pRE-symptomatic Alzheimer's Disease Screening questionnaire (PRE-ADS), found that variations in screening acceptability are influenced by both family history and cultural factors.

With 56.9% expressing a positive intention toward pre-symptomatic AD screening, the study underscores the need to tailor healthcare services based on cultural nuances.

Read the full article [here](#).

## GECONEU Learning Teaching Training (LTT) and Transnational Project Meeting (TPM) in Izmir



The GECONEU project marked a significant milestone with the successful organization of the Learning Teaching Training (LTT) on November 30th in Izmir. During this event, experts and professionals in the field received comprehensive training on the GECONEU course and its materials. Dr. Mehmet Kocabey, a medical geneticist, delivered a compelling presentation on Genetic Counseling in Neurodegenerative Disorders: From the Perspective of a Medical Geneticist in Turkey. Participants also delved into the GECONEU Course content and gained insights into its practical application. Subsequently, on December 1st, the project partners convened for a Transnational Project Meeting (TPM) in Izmir. Partners gathered to discuss crucial aspects of the project, including Project Overview, PR2: Development and design of the course and material, PR3: Design, Development, and Testing of a Service System for students & evaluation and learning, PR4: Genetic Counseling in Practice, and Project Management and Implementation. The meeting facilitated discussions on project results and future steps.

### Pilot phase

Post LTT and TPM, the pilot study commenced with the active participation of 20 students and 5 professionals from Belgium, Germany, Greece, Spain, and Turkey. The GECONEU course, an introductory program in Genetic Counseling for Neurodegenerative Disorders, is designed for students of Health and Life Sciences, Biomedical Sciences, and professionals in the field of Health Sciences.

Stay tuned for more updates from the GECONEU project by visiting our [website](#) and following us on social media as we continue to advance genetic counseling education and research in the field of neurodegenerative disorders. Thank you for your ongoing support.